Early Pembrolizumab Ups TNBC Responses.
Pembrolizumab plus chemotherapy may be an effective neoadjuvant therapy in patients with early-stage triple-negative breast cancer: In an interim analysis of the phase III KEYNOTE-522 trial, patients treated with the combination had a higher pathologic complete response rate and trended toward better event-free survival than those who received chemotherapy alone.